F
Fabien Zoulim
Researcher at French Institute of Health and Medical Research
Publications - 716
Citations - 40988
Fabien Zoulim is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 96, co-authored 641 publications receiving 35807 citations. Previous affiliations of Fabien Zoulim include Hotel Dieu Hospital & University of Orléans.
Papers
More filters
Journal ArticleDOI
Genome Replication, Virion Secretion, and e Antigen Expression of Naturally Occurring Hepatitis B Virus Core Promoter Mutants
Sameer Parekh,Fabien Zoulim,Sang Hoon Ahn,Adrienne Tsai,Jisu Li,Shigenobu Kawai,Nasser Khan,Christian Trepo,Jack R. Wands,Shuping Tong,Shuping Tong +10 more
TL;DR: In this article, the authors analyzed the biological properties of naturally occurring core promoter mutants of hepatitis B virus (HBV) by PCR from sera of HBeAg(+) individuals infected with genotype A. The double core promoter mutations were found to moderately enhance viral genome replication and reduce hepatitis B e antigen (HBeAg) expression.
Journal ArticleDOI
Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.
Xavier Causse,Hubert Godinot,Michèle Chevallier,P. Chossegros,Fabien Zoulim,Denis Ouzan,Jean-Paul Heyraud,T. Fontanges,Janice K. Albrecht,Carlton Meschievitz,Christian Trepo +10 more
TL;DR: It is concluded that 3 MU of interferon is a more effective dose than 1 MU for controlling disease activity in non-A, non-B chronic hepatitis patients and women and younger and noncirrhotic patients are more likely to respond.
Journal ArticleDOI
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
Marc Bourlière,Jean-Pierre Bronowicki,Victor de Ledinghen,Christophe Hézode,Fabien Zoulim,Philippe Mathurin,Albert Tran,Dominique Larrey,Vlad Ratziu,Laurent Alric,Robert H. Hyland,Deyuan Jiang,Brian P. Doehle,Phillip S. Pang,William T. Symonds,G. Mani Subramanian,John G. McHutchison,Patrick Marcellin,François Habersetzer,Dominique Guyader,Jean-Didier Grangé,Véronique Loustaud-Ratti,Lawrence Serfaty,Sophie Metivier,Vincent Leroy,Armand Abergel,Stanislas Pol +26 more
TL;DR: The shorter regimen, when given with ribavirin, provided similarly high SVR12 rates in previous non-responders with HCV genotype 1 and compensated cirrhosis and might, therefore, be useful to treat treatment-experienced patients with Cirrhosis if longer-term treatment is not possible.
Journal ArticleDOI
Management of antiviral resistance in patients with chronic hepatitis B.
Stephen Locarnini,Angelas Hatzakis,Jenny Heathcote,Emmet B. Keeffe,T. Jake Liang,David Mutimer,Jean-Michel Pawlotsky,Fabien Zoulim +7 more
TL;DR: Treating physicians are provided with a framework for the management of chronic hepatitis B in the context of antiviral resistance to aid monitoring and early diagnosis of drug resistance before disease progression occurs as a consequence of viral breakthrough.
Journal ArticleDOI
Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase.
Fabien Zoulim,Christoph Seeger +1 more
TL;DR: It is demonstrated that a tyrosine residue of the polymerase polypeptide is the site of a phosphodiester linkage with the first nucleotide of minus-strand DNA that is indispensable for the priming of reverse transcription.